Trump confirms Makary out at FDA
President Donald Trump confirmed on Tuesday that Marty Makary would be leaving his post atop the U.S. Food and Drug Administration.
While speaking to reporters on the White House lawn Tuesday, Trump said Makary would be leaving. He said FDA deputy commissioner Kyle Diamantes will take over as the adminsitration seeks a new leader of the federal agency.
“He was having some difficulty,” Trump said. “Marty is a terrific guy, but he’s going to go and lead a good life.”
Trump did not specify what kind of difficulty Makary experienced. Several reports circulated that there was an internal dispute over approval for flavored vapes at the FDA. The Wall Street Journal reported that Trump pressured Makary to approve fruit-flavored vapes, but he was hesitant to do so.
Trump said many people are seeking the job atop the agency.
Makary was expected to testify on Capitol Hill Wednesday to present the FDA’s budget for the upcoming fiscal year. Diamantes is expected to take his place.
Makary was confirmed to lead the FDA in March 2025. Since then, he’s sought to make several changes to the agency’s policies and change organizational structure. Makary sought to limit antidepressants for pregnant women and ban kratom byproducts.
“He’s a friend of mine, he’s a wonderful man and he’s going to be off,” Trump said of Makary.
Latest News Stories
Beecher Officials Review Recreational Fire Rules Following Smoke Complaints
Crete “Group Care” Home Approved for Senior Living
Fiscal Fallout: States continue to increase budgets despite end of COVID emergency
Colorado lost record $24 million to data scams in 2024
Trump vows to pause migration after D.C. shooting
Assaults against ICE up 1,153% in 11 months
Illinois quick hits: Deer harvest totals; IHSA voting begins
Texas officials seek to establish Turning Point chapters
National Guard member shot near White House dies
Chicago tenant groups call for eviction moratorium amid ICE raids
Illinois tax proposals dampen decline in small business uncertainty index
New Bar Approved in Frankfort Despite Board Opposition